press release

The same fully implanted, wireless device supporting motor recovery after stroke now enables thought-controlled computer use without additional surgery or hardware.   Freiburg, Germany, April 29, 2026 – CorTec GmbH today announced that the first participant in the University of Washington’s NIH-funded clinical trial of the Brain Interchange™ BCI system has successfully controlled a computer […]

Freiburg, Germany, April 23, 2026 – CorTec GmbH today announced that the U.S. Food and Drug Administration (FDA) has accepted the company into its Total Product Life Cycle Advisory Program (TAP), recognizing the Brain Interchange™ BCI system as a priority innovation in stroke motor rehabilitation. The TAP enrollment follows the recently granted FDA Breakthrough Device

Freiburg, Germany, April 08, 2026 — CorTec GmbH, a pioneer in fully implantable brain-computer interfaces (BCI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s  Brain Interchange™ system. The designation covers the use of direct cortical electrical stimulation to support motor recovery in people living with

Second implantation at Harborview Medical Center in Seattle marks continued progress in the FDA-approved study informed by promising results from the first participant. Freiburg, Germany, February 10, 2026 – CorTec GmbH, a pioneer in active implantable medical technologies, today announced the successful second implantation of its proprietary BrainComputer Interface (BCI) system, the Brain Interchange™, in

The University of Washington shared the inspiring story of a stroke patient who regained movement thanks to a pioneering brain implant technology developed by CorTec.   After two strokes, Matt Kidd’s left side was almost completely paralyzed. Years of therapy brought little progress, until he became part of a clinical trial at the University of

The closed-loop BCI system, developed entirely in Germany, is currently being evaluated in an FDA-approved clinical trial with stroke patients at Harborview Medical Center in Seattle, a part of UW Medicine   Freiburg, Germany, July 29, 2025 – CorTec GmbH, a pioneer in active implantable medical technologies, today announced the first human implantation of its

A Strengthened Leadership Team to Accelerate Growth and Innovation   CorTec GmbH, a pioneer in active implantable technologies and Brain-Computer Interface (BCI) systems, is pleased to announce the appointment of Dr. Frank Desiere as its new Chief Executive Officer (CEO). This significant leadership milestone highlights CorTec’s commitment to driving innovation and growth in the rapidly

CorTec GmbH, a leader in innovative implantable technologies, is pleased to announce a strategic partnership with Heraeus Medevio, based in Minneapolis, USA. This collaboration aims to support customers in the neuromodulation sector, from concept and small series production (CorTec) to large series production (Medevio). Together, the companies will deliver next-generation medical devices and drive innovation

CorTec has announced today that Institutional Review Board from University of Washington (IRB) has approved the Feasibility study for stroke rehabilitation using the Brain Interchange System. This marks a significant milestone and paves the way for the system’s clinical investigation in the United States. The IRB approval follows the recent Investigational Device Exemption (IDE) granted

CorTec has announced today that the US Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) application by the University of Washington School of Medicine (UW) involving the closed-loop Brain Interchange Implant System. This clinical study will investigate a novel stroke rehabilitation treatment using cortical stimulation to enhance plasticity within the brain.